mation, in particular glomerular, is often characterized by increased IL-6 levels. The in vivo relevance of IL-6 signaling in glomerular podocytes, which play central roles in most glomerular diseases, is unknown. Here, we show that in normal mice, podocytes express gp130, the common signal-transducing receptor subunit of the IL-6 family of cytokines. Following systemic IL-6 or LPS injection in mice, podocyte IL-6 signaling was evidenced by downstream STAT3 phosphorylation. Next, we generated mice deficient for gp130 in podocytes. Expectedly, these mice exhibited abrogated IL-6 downstream signaling in podocytes. At the age of 40 wk, they did not show spontaneous renal pathology or abnormal renal function. The mice were then challenged using two LPS injury models as well as nephrotoxic serum to induce crescentic nephritis. Under all conditions, circulating IL-6 levels increased markedly and the mice developed the pathological hallmarks of the corresponding injury models such as proteinuria and development of glomerular crescents, respectively. However, despite the capacity of normal podocytes to transduce IL-6 family signals downstream, there were no significant differences between mice bearing the podocyte-specific gp130 deletion and their control littermates in any of these models. In conclusion, under the different conditions tested, gp130 signaling was not a critical component of the (patho-)biology of the podocyte in vivo.
PODOCYTE INJURY AND ENGAGEMENT of podocytes in glomerular inflammation are hallmarks of progressive glomerular diseases (2, 32) . Understanding the mediators that damage podocytes and the mechanisms by which podocytes can modulate glomerular inflammation appears of paramount importance in designing novel therapeutic approaches to the growing tide of chronic kidney disease.
For more than 20 years, the IL-6 family of cytokines have been recognized to contribute to inflammatory glomerular disease (8, 21, 35) . IL-6 itself is mostly produced by leukocytes but can also be secreted from mesangial cells upon stimulation with angiotensin II and by podocytes following LPS administration in vivo (19, 24) . The major downstream effector of the IL-6 family signaling pathway, Signal transducer and activator of transcription (STAT) 3, has been implicated in renal diseases (5) . Very recently, deletion of STAT3 from podocytes has been described to be beneficial in the models of nephrotoxic serum nephritis and human immunodeficiency virus (HIV)-associated nephropathy (6, 11) . However, the role of IL-6 and the IL-6 family of cytokines in glomerular disease is not fully understood. For example, both anti-and proinflammatory effects of IL-6 have been described in models of renal diseases (13, 16, 29) .
Glycoprotein 130 (gp130) is the common signal-transducing membrane receptor unit of all IL-6 family of cytokines (except IL-31) and mediates signals mainly via the Janus kinase (JAK)/ STAT3 pathway and to some extent via the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways (9) . The IL-6 family of cytokines comprises IL-6, IL-11, IL-27, IL31, leukemia-inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), oncostatin-m (OSM), cardiotrophin-1 (CT-1), and cardiotrophin-like cytokine (CLC). Generation of an intracellular signal necessitates binding of the cytokine together with its cognate receptor (e.g., the IL-6 receptor; IL-6R) to gp130. Therefore, deletion of gp130 abrogates the capacity of all IL-6 family members to elicit intracellular signals. Expression of gp130 is relatively ubiquitous while the presence of the specific cytokine membrane receptor is more restricted (9) . This is illustrated by the IL-6R, which is mainly found on liver and immune cells (9) . In classic signaling, IL-6 binds to membrane-bound gp130 and IL-6R, while in trans-signaling, a soluble form of the IL-6R (sIL-6R) in complex with IL-6 serves to activate IL-6R-negative cells (9) . sIL-6R serum levels are 30 -50 ng/ml in health and increase two-to threefold during inflammation in both humans and mice (9) . Consequently, most gp130-positive cells (even if negative for the membrane-expressed IL-6R) are believed to become targets of IL-6 signaling once systemic IL-6 levels increase (14) .
Targeted disruption of gp130 in mice is lethal, leading to cardiac and hematopoietic deficiencies while data on the kidney phenotype are not available (37) .
To better understand the role of the IL-6 family of cytokines in the glomerulus, specifically the podocytes, we have studied gp130 expression and the consequences of deleting this common IL-6 family receptor on podocytes.
MATERIALS AND METHODS
Animals and experimental designs. Mice had ad libitum access to drinking water and standard chow. The gp130f/f (3) and gp130f/f, pod-creϩ/Ϫ (23) (gp130⌬pod) mice were bred on a mixed C57BL/ 6-FVB background for at least eight generations. Matched littermates were used for all experiments. All animal experiments were approved by the local government authorities.
For testing renal IL-6 responsiveness ( Fig. 1) , recombinant murine IL-6 (10 g; Immuno Tools, Friesoythe, Germany) was injected intravenously 15 min before euthanasia. The monoclonal rat antimouse IL-6 inhibitory antibody MP5-20F3 and isotype control (rat monoclonal anti-horseradish peroxidase/HRPN) were purchased from Bio-X-Cell (West Lebanon, NH), and 300 g were injected intraperitoneally (ip) 2 h before LPS. Fig. 1 . gp130 and downstream signaling in the normal mouse glomerulus. A: paraffin section, double-immunofluorescence using the polyclonal C-terminal gp130 antibody (used throughout the study). Most gp130 localizes to podocytes (arrows), and weak expression is detected in the endothelium and mesangium (arrowheads). Antigen specificity is suggested by the capacity of the immunizing antigen to abolish the gp130 signal. Far right: magnification of the inset. B: cryosection using the alternative monoclonal N-terminal gp130 antibody exhibiting a similar staining pattern and a corresponding IgG negative control. C-E: pSTAT3 triple-immunofluorescence and differential interference contrast (DIC) of cryosections using 4=,6-diamidino-2-phenylindole (DAPI) as a nuclear and synaptopodin as a podocyte marker. Nuclear pSTAT3 was negative in control mice (con) but equally induced following stimulation of mice with IL-6 (10 g iv, 15 min) and LPS (10 mg/kg ip, 2 h) with the strongest signal in podocytes (arrows), indicating induction of downstream signaling. Representative images are shown. F: quantification of pSTAT3-positive cells per glomerular cross section (gcs). The response to LPS was reduced by an anti-IL6 antibody but not by isotype IgG control. G: corresponding serum IL-6 levels confirming IL-6-induction by LPS and reduction by anti IL-6-treatment. In control mice IL-6 levels were below the detection limit of the assay (7.8 pg/ml). All original magnifications ϫ400. *P Յ 0.05; n ϭ 3/group, except for antibody treatments (n ϭ 4/group).
LPS from Escherichia coli serotype O26:B6 (L8274, Sigma-Aldrich) was prepared in sterile 0.9% NaCl and activated by ultrasound before injection (10 mg/kg ip). In the LPS (42 h) model, two injections of 10 mg/kg ip at 42 and 24 h before euthanasia were given and were accompanied by 0.9% NaCl (30 ml/kg sc) at 42, 24, and 18 h before euthanasia to prevent dehydration. Urine collection was performed in metabolic cages during the last 12-16 h before euthanasia.
Nephrotoxic serum nephrits (NTN) was induced by a single injection of 2.5 mg/g nephrotoxic serum (NTS) (30) spiked with 40 g of CpG oligonucleotides. Serum and 12-h urine collections using metabolic cages were obtained during the course of the model.
For the 24-h IL-6 challenge (see Fig. 5 ), murine IL-6 (2 g ip) was administered at 24, 18, 12, 6 , and 2 h before euthanasia. Urine was collected in metabolic cages during the last 12-16 h before euthanasia.
Immunostaining and histology. Kidneys were snap frozen in mounting agent, Tissue-Tek (Sakura Finetek) or fixed over 36 -48 h at 4°C in 4% formalin or methyl Carnoy's solution (60% ethanol, 30% chloroform, 10% glacial acetic acid). Five-micrometer cryosections were fixed with 4% paraformaldehyde for 15 min. and permeabilized with 0.2% Triton X-100. Two-micrometer formalinfixed paraffin sections were treated by an antigen retrieval protocol using unmasking solution (Vector Laboratories, Burlingame, CA). All sections were blocked using 10% donkey serum (Dianova, Hamburg, Germany) in PBS. Primary antibodies used are specified in Table 1 . Secondary antibodies for fluorescence were from donkeys, purified by a cross-reactivity panel, and conjugated with Cy3, Alexa 488, or DyLight 549 (Dianova). Appropriate secondary antibodies for immunohistochemistry were biotinylated (Vector) allowing for a DAB staining as described (26) . Methyl green was used for counterstaining. Slides for routine morphology were stained with periodic acid-Schiff (PAS).
Analyses were performed in a blinded fashion. Slides were scanned (Hamamatsu) or visualized using a fluorescent microscope (Zeiss LSM-710 or Keyence). For pSTAT3, podoplanin, synaptopodin, and CD3, 20 glomerular cross sections/animal were evaluated. pSTAT3-positive nuclei were counted automatically using Keyence BZ-II Analyzer Software. For experiments outlined in Fig. 2 , F, G, and I, a higher threshold was set to allow for the detection of mainly podocytes. This was possible because podocytes upon stimulation exhibit higher pSTAT3 signals than other glomerular cell types. Podoplanin, synaptopodin, and renal cortical F4/80 expression was quantified using Image J software version 1.45, and the area of positive signal was calculated as the percentage of total area. To assess the severity of NTN, 100 PAS-stained glomeruli/mouse were evaluated for crescents. Glomerular fibrinoid necrosis was assessed by a semiquantitative score as 0 ϭ absent; 1ϭ Ͻ25%; 2 ϭ 25 -50%; 3 ϭ 50 -75%; and 4 ϭ Ͼ75% of the glomerular tuft area.
Perfusion and preparation of isolated glomeruli. Glomeruli were isolated following perfusion with 20 ml 0.9% NaCl containing 2 ml Dynabeads M-450 Tosylactivated (Life Technologies) and subsequent collagenase kidney digestion using a magnetic particle concentrator (DynaMag TM-2,123.21D, Life Technologies).
Podocyte primary cultures. Podocyte primary cultures were prepared as detailed previously either from gp130f/f and gp130⌬pod animals ( Fig. 2) or Pod-rtTA/LC1/R26R animals by ␤-Galactosidase FACS-selection (for quantitative RT-PCR of endogenous IL-6R expression in normal podocytes), respectively (15) .
Western blotting. Tissue protein extracts were generated on ice using RIPA buffer (150 mM NaCl, 50 mM Tris·HCl, pH 7.4, 1% NP-40, 0.25% Na-deoxycholate) containing protease and phosphatase inhibitors (Halt, ThermoScientific). Equal amounts of protein (15 g) were loaded. Primary antibodies are listed in Table 1 . HRP-conjugated secondary antibodies were used (Vector), and detection was performed using ECL (32209, ThermoScientific) in a digital reader (LAS 3000, Fuji, Japan). Densitometry of bands was performed using Image J software.
PCR. Genotyping of tail DNA was performed using standard protocols. RNA was isolated using standard columns, and cDNA was synthesized using random primers. Real-time quantitative PCR was carried out using an ABI Prism 7300 sequence detector (Applied Biosystems). Quantitative data from the real-time RT-PCR were normalized using GAPDH as an internal control and calculated using the ⌬⌬CT-method. Primer sequences are provided in Table 2 .
Serum and urine measurements. Urinary total protein and creatinine levels, serum creatinine, albumin, and urea nitrogen levels were measured in a Vitros 250 reader using UPRO slides and Vitros chemistry products calibrator kit 10 (Ortho Clinical Diagnostics, Neckargemuend, Germany). Mouse IL-6 and albumin ELISAs were obtained from R&D Systems (Minneapolis, MN) and from Immunology Consultants Laboratory (Portland, OR), respectively.
Blood pressure measurement. A noninvasive computerized tailcuff system was used (Kent Scientific, Torrington, CT). Measurements were done at the same time of the day (0800 -1100) by the same operator and performed using restraining tubes on a warmed plate (36°C) at an ambient room temperature of 24°C.
Statistical analyses. Values are means Ϯ SE. Statistical significance was evaluated using GraphPad Prism, version 6.0b (GraphPad Software, San Diego, CA). ANOVA with Tukey's post hoc test was applied to all analyses, except for the Kruskal-Wallis test with Dunn's posttest (see Fig. 4 , F and G), and a two-sided t-test (Table 3 , see Fig. 5 ). Statistical significance was defined as p Յ 0.05.
RESULTS

Expression of gp130 and its downstream signaling in normal mouse glomeruli.
In normal mice, gp130 was primarily expressed in podocytes and to a lesser extent in endothelial and mesangial cells. Similar staining patterns were obtained using antibodies directed against the gp130 C and N terminus, respectively (Fig. 1, A and B) . The C-terminal antibody was subsequently used throughout the study.
To assess the capacity of glomerular cells to transduce IL-6 cytokine signals, animals received a single injection of either IL-6 or LPS. LPS induces high systemic IL-6-levels and gp130-dependent STAT3 phosphorylation in the liver (34) . In normal glomeruli, pSTAT3 was absent, but it was induced following both IL-6 or LPS with a pronounced signal in podocytes. An inhibitory anti-IL-6 antibody, but not isotype IgG administered 2 h before LPS treatment attenuated the response, corroborating its significant dependency on IL-6 ( Fig. 1, C-F) . Assessment of the corresponding serum IL-6 levels confirmed its induction by LPS and reduction by the IL-6 antibody (Fig. 1G) . The findings suggest that IL-6 alone was sufficient to induce pSTAT3 in podocytes and that it was also required for at least part of the pSTAT3 response elicited by LPS.
The IL-6R was not detectable by immunofluorescence in podocytes using an anti C-terminal antibody, while liverpositive controls showed a very strong signal. This was confirmed at the mRNA level, where expression of the IL-6R was 10 -20 times lower in podocyte primary cultures and the renal cortex than in the liver (data not shown). Consequently, podocytes are expected to receive their IL-6 signals via transsignaling.
Podocyte-specific deletion of gp130 and its downstream signaling in mice. Podocyte-specific deletion of gp130 was achieved by crossing pod-Cre mice expressing cre-recombinase under the control of the podocin promoter (23) with gp130f mice in which the transmembrane domain encoding exon 16 of gp130 is flanked by lox-P sites (3) (Fig. 2A) . Cre-mediated excision of exon 16 generates a truncated gp130 molecule (gp130⌬ lacking the C-terminal 306 amino acids that include the transmembrane domain, thus leading to its loss from the cell) (3, 34) . Figure. 2 , B-E, demonstrates the occurrence of gp130⌬ mRNA in glomeruli and loss of gp130 immunoreactivity from glomeruli and podocytes in (gp130f/f, pod-Creϩ/Ϫ) mice, i.e., generation of gp130⌬pod mice. Importantly, in these mice induction of glomerular pSTAT3 by LPS was abrogated by 92%, confirming the requirement of gp130 for this activation and providing evidence for the podocyte-specific deletion of gp130 at a functional level in the majority of podocytes (Fig. 2, F-J) . This was also confirmed by RT-PCR of podocyte primary cultures derived from gp130f/f and gp130⌬pod animals, respectively (Fig. 2K) .
Normal and aging phenotype of gp130f/f and gp130⌬pod mice. Both male and female mice aged 12-40 wk were examined with respect to renal histology, weight, blood pressure, renal serum parameters, proteinuria, WT-1 as a podocyte marker, and PCNA as a proliferation marker. All these studies revealed no differences among the groups (Fig.  2L and Table 3) .
LPS-induced podocyte injury in gp130f/f and gp130⌬pod mice. In the experiments outlined above, we had used the short-term administration of LPS to induce high systemic IL-6 levels to monitor gp130 downstream signaling. LPS administration also represents an established model of podocyte injury, resulting in foot process effacement and proteinuria (28) . The use of LPS appears especially attractive for the study of gp130⌬pod mice since the major mechanism of LPS recognition, the Toll-like receptor (TLR) 4 pathway, has been recently Normal (5) Normal (5) Values are means Ϯ SE (n) by t-test. wk, animal age in weeks; gcs, Glomerular cross section; NS, nonsignificant.
shown to interact with gp130/pSTAT3 signaling, resulting in a hypersensitivity to LPS (10) . Both a 24-and 48-h model have been described in which LPS (10 mg/kg ip) is administered once (28) or twice every 24 h, respectively (4, 7). The latter was modified by us to a duration of 42 h. Model-induced death rates were 0% in the LPS (24 h) and 28% (5 animals) per group in the LPS (42 h) models, respectively. Both LPS models induced a dose-dependent increase in serum creatinine, albuminuria, and serum IL-6 levels (Fig. 3, 
A-C).
There was a positive correlation of IL-6 levels and albuminuria: r 2 ϭ 0.65, P Յ 0.001. Expectedly, LPS significantly induced glomerular pSTAT3 only in gp130f/f but not in gp130⌬pod animals (difference 70%) (Fig. 3D ). This rate from immunohistochemical analysis probably underestimated the gp130 deletion in podocytes owing to the impossibility to adjust for background from other glomerular cells (compare with 92% in Fig. 2I ). LPS-induced podocyte injury was evidenced by decreased glomerular podoplanin and synaptopodin Fig. 3 . LPS-induced injury models. Female age-matched gp130f/f and gp130⌬pod mice (16 -24 wk) were either left untreated (con) or were injected once with LPS 24 h before euthanasia (LPS 24 h) or, in an accelerated model, (LPS 42 h), treated with 2 subsequent injections of LPS at 42 and 24 h before euthanasia (10 mg/kg ip for all injections; see MATERIALS AND METHODS for further details). As a general rule, these models were effective in inducing injury as indicated by significant changes in parameters compared with control but revealed no differences between gp130f/f and gp130⌬pod animals. A-C: serum and urine parameters. Note that serum IL-6 measured 24 h following LPS induction exhibits significantly lower (postpeak) levels compared with measurement after 2 h (Figs. 1 and 2) . expression, accompanied by a compensatory increase in the corresponding mRNA synthesis of podoplanin, a phenomenon that has been described previously (see the DISCUS-SION) (Fig. 3, E-J) . However, neither LPS model revealed a significant difference between gp130f/f and gp130⌬pod animals (Fig. 3) . Podoplanin expression has been described to be stimulated by gp130 signaling in keratinocytes and endothelium (12, 25) , leading to the expectation that gp130⌬pod kidneys should exhibit lower podoplanin expression upon stimulation. Consistent with this, subanalysis of Fig. 3G by a one-sided t-test revealed a statistically significant 25% reduction (P ϭ 0.028) in the case of the LPS (24 h) model. However, this did obviously not translate to the protein level (Fig. 3F) .
Nephrotoxic nephritis in gp130f/f and gp130⌬pod mice. Both parietal epithelial cells and podocytes contribute to crescent formation, as occurs in nephrotoxic nephritis (NTN) (32) . NTN was therefore used as an additional model to investigate the role of gp130 in the podocyte. STAT3 in the podocyte has been implicated in this model (6), and we found increasing STAT3 and pSTAT3 protein levels in kidney lysates during NTN (own unpublished observations). Similar to LPS injec- Fig. 4 . Nephrotoxic serum nephritis (NTN). Male mice aged 12 wk were used. A-C: Time course of serum and urine parameters indicating successful induction of NTN but no significant differences between gp130f/f and gp130⌬pod animals. D, day. D and E: following 14 days of NTN, gp130f/f and gp130⌬pod animals exhibited similar levels of crescent (arrows) and fibrinoid necrosis (FN) formation. Macrophage-specific F4/80, and T-lymphocyte-specific CD3 staining also showed similar infiltration rates of these cells in both groups (G and dotted lines ϭ glomeruli). Representative images are shown. F-I: quantitative analysis corresponding to D and E. J and K: real-time RT-PCR of renal cortex, revealing no difference between gp130f/f and gp130⌬pod. Original magnifications ϫ400. *P Յ 0.05; gp130f/f: n ϭ 10, gp130⌬pod: n ϭ 13 animals for all histological, immunological, mRNA, and D14 serum/urine analyses. Remaining serum/urine time points: n ϭ 6 -8/group, D7 proteinuria: 3-4/group. tion, NTN was associated with increased systemic IL-6 levels, which exhibited an initial peak and remained above normal throughout: pre: below detection limit of 7.8 pg/ml; 6 h: 17,710 Ϯ 2,882 pg/ml; 12 h: 7,937 Ϯ 1,589 pg/ml; day 2: 36 Ϯ 3 pg/ml; day 7: 22 Ϯ 3 pg/ml; day 14: 15 Ϯ 3 pg/ml (n ϭ 3/group). A beneficial role of IL-6 in this model is suggested by studies using the administration and inhibition of IL-6, respectively (16, 25a) . While serum, urine, and histopathological parameters indicated successful induction of NTN, none of the readout parameters were significantly different between gp130f/f and gp130⌬pod mice (Fig. 4) .
IL-6 challenge in normal mice. To better understand the negative results of the LPS and NTN studies, we injected IL-6 into normal gp130 f/f mice over 24 h (cumulative dose of 10 g by repeated ip injection) (Fig. 5 ). IL-6 bioactivity was evidenced by a significant increase in the mRNA expression of liver acute-phase proteins. In line with the literature and the subanalysis of the LPS (24 h) model (see above), renal podoplanin mRNA was upregulated by IL-6 (Fig. 5G) . However, other renal end points were not affected (Fig. 5) . It is worth noting that this negative result does not challenge the rationale behind the LPS and NTN-studies. IL-6 has been shown previously to exhibit the properties of a factor that can be essential for, but at the same time insufficient on its own to induce pathology in disease models, e.g., in murine muscle wasting (38) . Moreover, by deleting gp130, the present study probed the role of the entire family of gp130-dependent cytokines, not only IL-6.
DISCUSSION
In the present study, we have attempted to dissect the role of IL-6 family cytokine signaling in podocytes. Given that gp130 is the signal transduction unit of all of the IL-6 family of cytokines (except for IL-31), this provided a unique opportunity to assess the function of a whole group of cytokines in parallel.
The first major finding of this study was that podocytes express gp130 and respond reliably to appropriate stimuli of gp130 signal transduction in vivo. These data provide an important extension of previous reports on gp130 signaling in podocytes, which were exclusively performed in vitro. Cultured podocytes have been described to express gp130 and low amounts of IL-6R and to respond to IL-6 stimulation with induction of gelatinase-associated lipocalin (Lcn/Ngal), peroxisome proliferator-activated receptor-␥ coactivator (PGC 1-␣) and podocyte apoptosis (17, 19) . Other IL-6 family cytokines acting via gp130 that have been linked to the podocyte include LIF, reported to protect cultured podocytes from high glucoseinduced apoptosis, CLC, a putative proteinuria permeability factor in focal segmental glomerulosclerosis (FSGS), and CNTF, which is upregulated by steroids in cultured podocytes (22, 27, 36) .
Our second major finding was that three different disease models, all characterized by markedly increased circulating IL-6 levels, remained unaffected by the deletion of gp130 from podocytes. Consistent with this, the gp130 podocyte-specific deletion also did not result in a spontaneous phenotype in young and aging mice. IL-6 when administered alone increased renal podoplanin mRNA but did not cause a further renal phenotype, suggesting the presence of additional factors in the LPS and NTN models leading to damage.
According to our data, podocyte injury and proteinuria following LPS administration are not significantly modified by the concomitant high systemic IL-6 levels or gp130/pSTAT3-induced hypersensitivity as suggested (10) , leaving LPS recognition by podocyte-expressed Toll-like receptor-4 (TLR-4) as the main initial signaling step involved (1, 28, 33) . Consequently, the recently described induction of IL-6 synthesis by LPS in podocytes in vivo (19) is not likely to represent a relevant autocrine mechanism promoting injury in this model. The increase in LPS-induced proteinuria in IL-6 Ϫ/Ϫ mice reported by the same authors may thus result from nonrenal effects or effects on other renal cell types than the podocytes.
LPS-induced attenuation of podoplanin and synaptopodin immunoreactivity was paralleled by an upregulation of the corresponding mRNAs. Similarly, mRNA encoding these proteins was upregulated during NTN. While this may at first seem counterintuitive, upregulation of podocyte markers at the message level during states of stress has been described in animal models and human samples of FSGS and minimalchange disease (18, 20) . These data suggest similarities between podocyte injury in rodents and in humans and support a model of increased turnover of podocyte proteins in states of stress.
Glomerular crescent formation during NTN mostly derives from parietal epithelial cells (32) , but some podocyte contribution also exists: in a recent cell lineage-tracing study employing the same nephrotoxic serum as described herein, parietal epithelial cells represented the majority of cells within crescents but cells of podocytic origin amounted to 13% (32) . Identifying mediators of the cell-cell cross talk between parietal epithelial cells and podocytes is not only of central relevance for crescentic nephritis but also for glomerular scar formation, i.e., FSGS (31) . Our study largely excludes IL-6-type cytokines as contributors to this cross talk during crescentic nephritis, at least as far as the podocytes are concerned. Specific studies of gp130 signaling in the parietal cells remain to be performed.
As mentioned above, Dai et al. (6) reported the podocytespecific deletion of STAT3 to markedly benefit the course of NTN by a reduction in crescent formation and proliferation markers. Activation of the STAT3 pathway is redundant, receiving cues not only from IL-6/gp130 but also from other membrane receptor pathways such as the epidermal growth factor (EGF) receptor, the pathogenic role of which during NTN has also recently been established (4). Dai et al. (6) hypothesized that both IL-6 and EGF may be involved in the pathogenesis of NTN after demonstrating that both molecules induce pSTAT3 in cultured podocytes. Our findings now provide indirect evidence for a dominance of the EGF pathway in this context.
A potential limitation of our approach of conditional gene ablation is the possibility of generating a mosaic pattern of podocytic gp130 deletion caused by variable penetrance of cre-recombinase activity. However, our analysis of podocyte primary cultures (Fig. 2K) and of inducible pSTAT3 signals in glomerular nuclei of gp130⌬pod mice showed a very robust pattern of signal loss (70 -92% in Figs. 3D and 2I , respectively), arguing against significant mosaicism, especially since here the rate of podocyte-specific deletion may be underestimated due to background signal from nonpodocytic glomerular cells. The marked reduction in both gp130 and pSTAT3 in our gp130⌬pod mice suggests that podocytes are the major glomerular cell type expressing gp130.
Collectively, these data suggest that under the tested inflammatory conditions, gp130 is not essential for the biology of the podocyte in vivo. The negative findings of the present study should not be extended beyond the disease models examined. In vitro data in other contexts, e.g., of high glucose-induced apoptosis (17) , suggest other potential roles for IL-6 signaling pathways in podocytes, which remain to be scrutinized by in vivo studies.
